Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06113679 · ClinicalTrials.gov registry record · NA
Pilot Randomized Study of RD-X19 Tx Device in Subjects With PCC (Long Covid) in the Outpatient Setting
A NA study, sponsored by EmitBio.
- Terminated
- Registry status
- NA
- Development phase
- 41
- Enrollment target
NCT06113679: Clinical Trial NA study, sponsored by EmitBio.
NCT06113679 is a NA study that was terminated before completion, run by EmitBio. The registered enrollment target is 41 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06113679, a NA study, was terminated before completion, sponsored by EmitBio.
- TERMINATED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
Study Summary
Duration of Treatment: 7 days, 2 times per day. Following Randomization on Week 1 Day 1, Subjects will continue to have televisits and rate symptoms and upright activity weekly during a 5 week follow up. Subjects will be followed via in clinic visits at week 2/day 8 (+3/-0 days) and Week 6 / day 36, (+3/-3days). Subjects will receive a weekly televisit during Week 3 / day 15 (+3/-3), Week 4 / day 22 (+3/-3), and Week 5 / day 29 (+3/-3).
Primary Outcome
Improvement of one or more primary PCC signs/symptom(s) - cough, fatigue, shortness of breath, cognitive dysfunction/brain fog as compared to sham, with or without fluctuation.
Interventions
- DEVICE RDX-19
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2023-10-30 |
| Est. Completion | 2024-06-21 |
| Phase | NA |
Why NCT06113679 stopped before completion
NCT06113679 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which RDX-19 is the first listed.
NCT06113679 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06113679 about?
NCT06113679 is a clinical study titled "Pilot Randomized Study of RD-X19 Tx Device in Subjects With PCC (Long Covid) in the Outpatient Setting". Duration of Treatment: 7 days, 2 times per day. Following Randomization on Week 1 Day 1, Subjects will continue to have televisits and rate symptoms and upright activity weekly during a 5 week follow up. Subjects will be followed via in clinic visits at week 2/day 8 (+3/-0 days) and Week 6 / day 36...
What is the current status of trial NCT06113679?
This trial is currently terminated. It is a NA study. The enrollment target is 41 participants. The study started on 2023-10-30. Estimated completion is 2024-06-21.
What interventions are being tested in trial NCT06113679?
The interventions under investigation include: RDX-19 (DEVICE).
Who is sponsoring clinical trial NCT06113679?
This trial is sponsored by EmitBio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06113679's enrollment target sits among peer trials
41 1446th of 2000 higher than 554 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI